| Mr Christopher Lee Furbee, PA-C | |
|
3551 Roger Brooke Dr, Fort Sam Houston, TX 78234-4504 | |
| (210) 539-9582 | |
| Not Available |
| Full Name | Mr Christopher Lee Furbee |
|---|---|
| Gender | Male |
| Speciality | Physician Assistant |
| Location | 3551 Roger Brooke Dr, Fort Sam Houston, Texas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083790307 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363A00000X | Physician Assistant | 1058339 (* (Not Available)) | Secondary |
| 363A00000X | Physician Assistant | PA00780 (Rhode Island) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Mr Christopher Lee Furbee, PA-C 3551 Roger Brooke Dr, Fort Sam Houston, TX 78234-4504 Ph: (210) 539-9582 | Mr Christopher Lee Furbee, PA-C 3551 Roger Brooke Dr, Fort Sam Houston, TX 78234-4504 Ph: (210) 539-9582 |
News Archive
A team of researchers, led by Ashley Moffett, at the University of Cambridge, United Kingdom, has shed new light on genetic factors that increase susceptibility to and provide protection from common disorders of pregnancy, specifically recurrent miscarriage, preeclampsia, and fetal growth restriction.
In this interview, Jolanta Vidugiriene, a Senior Research Scientist at Promega Corporation, talks to News-Medical about tools for studying metabolism in NAFLD/NASH research.
As anyone familiar with the X-Men knows, mutants can be either very good or very bad - or somewhere in between. The same appears true within cancer cells, which may harbor hundreds of mutations that set them apart from other cells in the body; the scientific challenge has been to figure out which mutations are culprits and which are innocent bystanders.
Seahorse Bioscience, the world leader in manufacturing instrumentation and assay kits for measuring cellular metabolism, has announced the launch of its newest product, the XF Palmitate-BSA FAO Reagent, eliminating the need for radioactivity in fatty acid oxidation (FAO) assays.
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for a once-daily fixed-dose combination of the NS5A inhibitor ledipasvir (LDV) 90 mg and the nucleotide analog polymerase inhibitor sofosbuvir (SOF) 400 mg for the treatment of chronic hepatitis C genotype 1 infection in adults.
› Verified 3 days ago
Jesse Gronsky, PA-C Physician Assistant Medicare: Not Enrolled in Medicare Practice Location: 3551 Roger Brooke Dr, Fort Sam Houston, TX 78234 Phone: 210-916-9900 | |
Michael David Gianelle, PA-C Physician Assistant Medicare: Not Enrolled in Medicare Practice Location: 3551 Roger Brooke Dr, Fort Sam Houston, TX 78234 Phone: 210-916-1154 | |
Mr. Cameron Darius Clement, PA-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 3880 Roger Brooke Dr., C/o General Surgery Dept/sammc, Fort Sam Houston, TX 78234 Phone: 509-590-8908 | |
William Grisham, PA-C Physician Assistant Medicare: Not Enrolled in Medicare Practice Location: 3551 Roger Brooke Dr, Fort Sam Houston, TX 78234 Phone: 615-987-2487 | |
John Mcfall, Physician Assistant Medicare: Not Enrolled in Medicare Practice Location: 3551 Roger Brooke Dr, Fort Sam Houston, TX 78234 Phone: 210-916-8764 | |
Guy-raphael Toussaint, PA-C Physician Assistant Medicare: Not Enrolled in Medicare Practice Location: 3551 Roger Brooke Dr, Fort Sam Houston, TX 78234 Phone: 210-539-9582 |